Cost of product for revenue recognized was $1.2 million during the quarter ended June 30, 2013, compared to $0.4 million for the comparable period in 2012. The increase of $0.8 million was primarily attributable to the cost of inventory associated with revenue recognized during the quarter, current period freight and warehousing costs and a write-off of excess and obsolete inventory.
Research and development expenses were $4.9 million for the second quarter of 2013 compared to $5.0 million for the same period in 2012. Selling, general and administrative expenses were $3.4 million for both the second quarter of 2013 and the second quarter of 2012.
The Company reported a net loss of $7.9 million or $0.23 per share for the second quarters of both 2013 and 2012.
Revenue for the six months ended June 30, 2013 was $3.6 million compared to $40.2 million in the same period of 2012. The year-over-year decrease was primarily related to $38.9 million in deferred revenue which was recognized as a result of the termination of the Telles joint venture in early 2012. Product revenue, grant revenue and research and development revenue increased by $1.2 million, $0.5 million and $0.6 million, respectively, during the first six months of 2013 compared to the first six months of 2012.
Cost of product revenue was $1.8 million during the six months ended June 30, 2013 compared to $0.5 million for the comparable period in 2012. The $1.3 million increase is primarily attributable to the cost of inventory sold during the period
|SOURCE Metabolix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved